Metabolic dysfunction-associated steatotic liver disease and gastroesophageal reflux disease: a mendelian randomization study in European and East Asian populations

被引:0
|
作者
Su, Chen'guang [1 ]
Liao, Zheng [1 ]
Li, Hewen [2 ]
Pei, Yinxuan [1 ]
Wang, Zixiang [1 ]
Li, Jian [1 ]
Liu, Jinlong [1 ,3 ]
机构
[1] Chengde Med Univ, Dept Hepatobiliary Surg, Affiliated Hosp, Chengde, Hebei, Peoples R China
[2] Chengde Med Univ, Dept Minimally Invas Spine Surg, Affiliated Hosp, Chengde, Hebei, Peoples R China
[3] Hebei Key Lab Panvasc Dis, Chengde, Hebei, Peoples R China
关键词
metabolic dysfunction-associated steatotic liver disease; gastroesophageal reflux disease; mendelian randomization; causal effect; genome-wide association studies; ALANINE AMINOTRANSFERASE; RISK-FACTORS; ESOPHAGITIS; PREVALENCE; OBESITY; INSTRUMENTS; SYMPTOMS; BIAS;
D O I
10.3389/fgene.2024.1428334
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Background Numerous observational studies have shown a potential association between metabolic dysfunction-associated steatotic liver disease (MASLD) and gastroesophageal reflux disease (GERD). However, causality is unclear. This study utilized genome-wide association study (GWAS) genetic data to explore the causal relationship between MASLD and GERD in European and East Asian populations. Methods This study utilized a bidirectional, two-sample Mendelian randomization (MR) approach. All disease data were obtained from the GWAS database, and single nucleotide polymorphisms strongly associated with exposure were selected as instrumental variables. The inverse variance weighted (IVW) method is primarily utilized to evaluate the causal relationship between exposure and outcome. Finally, sensitivity analyses were performed to ensure the robustness of the results. Results The IVW estimates indicated that non-alcoholic fatty liver disease (NAFLD) (odds ratio (OR) = 1.054, 95% confidence interval (CI), 0.966-1.150, p = 0.236) and percent liver fat (OR = 0.977, 95% CI, 0.937-1.018, p = 0.258) in European population were not linked to a higher risk of GERD. However, GERD in European population was associated with an increased risk of NAFLD (OR = 1.485, 95% CI, 1.274-1.729, p < 0.001) and percent liver fat (OR = 1.244, 95% CI, 1.171-1.321, p < 0.001). In addition, the IVW analysis in East Asian population showed that alanine aminotransferase (ALT) was associated with an increased risk of GERD (OR = 2.305, 95% CI, 1.241-4.281, p = 0.008), whereas aspartate aminotransferase (AST) had no causal effects on GERD risk (OR = 0.973, 95% CI, 0.541-1.749, p = 0.926). Furthermore, the associations between GERD and ALT (OR = 1.007, 95% CI, 0.998-1.015, p = 0.123) or AST (OR = 1.004, 95% CI, 0.997-1.012, p = 0.246) were not significant. After removing outliers, a significant correlation between GERD and ALT was observed (OR = 1.009, 95% CI, 1.001-1.016, p = 0.020). Conclusion There was reverse causality between MASLD and GERD in European population, while there was bidirectional causality between a proxie for MASLD (ALT) and GERD in East Asian population. This study can provide novel insights into cross-ethnic genetic research on MASLD and GERD.
引用
收藏
页数:12
相关论文
共 50 条
  • [21] Mechanobiology in Metabolic Dysfunction-Associated Steatotic Liver Disease and Obesity
    Rudolph, Emily L.
    Chin, LiKang
    CURRENT ISSUES IN MOLECULAR BIOLOGY, 2024, 46 (07) : 7134 - 7146
  • [22] Phytonanotherapy for the Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease
    Nendouvhada, Livhuwani P.
    Sibuyi, Nicole R. S.
    Fadaka, Adewale O.
    Meyer, Samantha
    Madiehe, Abram M.
    Meyer, Mervin
    Gabuza, Kwazikwakhe B.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (11)
  • [23] Metabolic dysfunction-associated steatotic liver disease and gut microbiota
    Petryna, Vitalii
    JOURNAL OF HEPATOLOGY, 2024, 80 : S285 - S285
  • [24] Update in lean metabolic dysfunction-associated steatotic liver disease
    Sato-Espinoza, Karina
    Chotiprasidhi, Perapa
    Huaman, Mariella R.
    Diaz-Ferrer, Javier
    WORLD JOURNAL OF HEPATOLOGY, 2024, 16 (03) : 452 - 464
  • [25] Metabolic dysfunction-associated steatotic liver disease: A silent pandemic
    Samanta, Arghya
    Sen Sarma, Moinak
    WORLD JOURNAL OF HEPATOLOGY, 2024, 16 (04)
  • [26] Postbiotic supplementation for metabolic dysfunction-associated steatotic liver disease
    Savytska, Maryana
    Baka, Olena
    Manzhalii, Elina
    Kyriienko, Dmytro
    Falalyeyeva, Tetyana
    Zhayvoronok, Maksym
    Kovalchuk, Oleksandr
    Deresh, Nataliya
    Grygoriev, Fedir
    Kobyliak, Nazarii
    JOURNAL OF HEPATOLOGY, 2024, 80 : S610 - S611
  • [27] Advances in research on metabolic dysfunction-associated steatotic liver disease
    Wang, Jiawang
    Wang, Zhongyu
    Yu, Yao
    Cheng, Si
    Wu, Jianping
    LIFE SCIENCES, 2025, 362
  • [28] Elucidating cuproptosis in metabolic dysfunction-associated steatotic liver disease
    Li, Yamei
    Qi, Ping
    Song, Si -Yuan
    Wang, Yiping
    Wang, Hailian
    Cao, Peng
    Liu, Yu 'e
    Wang, Yi
    BIOMEDICINE & PHARMACOTHERAPY, 2024, 174
  • [29] Natural history of metabolic dysfunction-associated steatotic liver disease
    Lekakis, Vasileios
    Papatheodoridis, George, V
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2024, 122 : 3 - 10
  • [30] Metabolic Dysfunction-Associated Fatty Liver Disease Increases the Risk of Gastroesophageal Reflux Symptoms
    He, Yuan
    Duan, Zhi-Jun
    Wang, Cheng-Fang
    Wei, Yu-Shan
    Cai, Ming-Xu
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2022, 15 : 199 - 207